JP2014520784A - 抗ｃｄ２０抗体と抗ｇｍ−ｃｓｆ抗体との治療的組合せおよびその使用 - Google Patents
抗ｃｄ２０抗体と抗ｇｍ−ｃｓｆ抗体との治療的組合せおよびその使用 Download PDFInfo
- Publication number
- JP2014520784A JP2014520784A JP2014517813A JP2014517813A JP2014520784A JP 2014520784 A JP2014520784 A JP 2014520784A JP 2014517813 A JP2014517813 A JP 2014517813A JP 2014517813 A JP2014517813 A JP 2014517813A JP 2014520784 A JP2014520784 A JP 2014520784A
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- region
- csf
- antibody
- antibody specific
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001225 therapeutic effect Effects 0.000 title description 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 44
- 238000011282 treatment Methods 0.000 claims abstract description 30
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 18
- 230000036210 malignancy Effects 0.000 claims abstract description 14
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 13
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 93
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 89
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 88
- 239000011885 synergistic combination Substances 0.000 claims description 30
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 28
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 28
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 27
- 208000032839 leukemia Diseases 0.000 claims description 15
- 206010025323 Lymphomas Diseases 0.000 claims description 14
- 201000001320 Atherosclerosis Diseases 0.000 claims description 10
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 10
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 10
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 9
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 8
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 8
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 7
- 208000006673 asthma Diseases 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 7
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 7
- 210000003563 lymphoid tissue Anatomy 0.000 claims description 7
- 201000006417 multiple sclerosis Diseases 0.000 claims description 7
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 claims description 6
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 6
- 208000034578 Multiple myelomas Diseases 0.000 claims description 6
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 claims description 6
- 206010037779 Radiculopathy Diseases 0.000 claims description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 6
- 230000001684 chronic effect Effects 0.000 claims description 6
- 230000003210 demyelinating effect Effects 0.000 claims description 6
- 210000004877 mucosa Anatomy 0.000 claims description 6
- 208000006473 polyradiculopathy Diseases 0.000 claims description 6
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 claims description 6
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims description 5
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 5
- 208000011231 Crohn disease Diseases 0.000 claims description 5
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 5
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 5
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 5
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 5
- 208000017604 Hodgkin disease Diseases 0.000 claims description 5
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 5
- 201000002481 Myositis Diseases 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 5
- 206010046851 Uveitis Diseases 0.000 claims description 5
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 5
- 201000008937 atopic dermatitis Diseases 0.000 claims description 5
- 230000001363 autoimmune Effects 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 5
- 208000010643 digestive system disease Diseases 0.000 claims description 5
- 208000024908 graft versus host disease Diseases 0.000 claims description 5
- 208000024557 hepatobiliary disease Diseases 0.000 claims description 5
- 208000002780 macular degeneration Diseases 0.000 claims description 5
- 201000008383 nephritis Diseases 0.000 claims description 5
- 230000004770 neurodegeneration Effects 0.000 claims description 5
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 5
- 201000000306 sarcoidosis Diseases 0.000 claims description 5
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 4
- 208000004296 neuralgia Diseases 0.000 claims description 4
- 208000021722 neuropathic pain Diseases 0.000 claims description 4
- 210000000416 exudates and transudate Anatomy 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 208000003926 Myelitis Diseases 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 88
- 229960004641 rituximab Drugs 0.000 description 30
- 241000699670 Mus sp. Species 0.000 description 16
- 239000000243 solution Substances 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 238000002648 combination therapy Methods 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 230000002195 synergetic effect Effects 0.000 description 8
- 229960002450 ofatumumab Drugs 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 6
- 229960000106 biosimilars Drugs 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 229960005267 tositumomab Drugs 0.000 description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 229950000815 veltuzumab Drugs 0.000 description 5
- 241000282567 Macaca fascicularis Species 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000002768 hair cell Anatomy 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 229950005751 ocrelizumab Drugs 0.000 description 4
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 3
- 238000012286 ELISA Assay Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010065857 Primary Effusion Lymphoma Diseases 0.000 description 3
- 229960000074 biopharmaceutical Drugs 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 206010001881 Alveolar proteinosis Diseases 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 108700042805 TRU-015 Proteins 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000011712 cell development Effects 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 208000037765 diseases and disorders Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- 229960003347 obinutuzumab Drugs 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- FZDFGHZZPBUTGP-UHFFFAOYSA-N 2-[[2-[bis(carboxymethyl)amino]-3-(4-isothiocyanatophenyl)propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical group OC(=O)CN(CC(O)=O)C(C)CN(CC(O)=O)CC(N(CC(O)=O)CC(O)=O)CC1=CC=C(N=C=S)C=C1 FZDFGHZZPBUTGP-UHFFFAOYSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 108050001413 B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 208000023611 Burkitt leukaemia Diseases 0.000 description 1
- 208000006547 Central Nervous System Lupus Vasculitis Diseases 0.000 description 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 229940126611 FBTA05 Drugs 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 102100038009 High affinity immunoglobulin epsilon receptor subunit beta Human genes 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000878594 Homo sapiens High affinity immunoglobulin epsilon receptor subunit beta Proteins 0.000 description 1
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 description 1
- 101100495232 Homo sapiens MS4A1 gene Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100033461 Interleukin-17A Human genes 0.000 description 1
- 208000005777 Lupus Nephritis Diseases 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- 201000003791 MALT lymphoma Diseases 0.000 description 1
- 101150098873 MS4A1 gene Proteins 0.000 description 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 229940124691 antibody therapeutics Drugs 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 229940126587 biotherapeutics Drugs 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000011235 central nervous system lupus Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- FOCAHLGSDWHSAH-UHFFFAOYSA-N difluoromethanethione Chemical compound FC(F)=S FOCAHLGSDWHSAH-UHFFFAOYSA-N 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 201000006569 extramedullary plasmacytoma Diseases 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 102000046157 human CSF2 Human genes 0.000 description 1
- 210000003480 igg memory b cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002871 immunocytoma Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003960 inflammatory cascade Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229940036646 iodine-131-tositumomab Drugs 0.000 description 1
- 210000002202 late pro-b cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229950003734 milatuzumab Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- 229950007708 namilumab Drugs 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 229950009090 ocaratuzumab Drugs 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 210000003720 plasmablast Anatomy 0.000 description 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- 229960002530 sargramostim Drugs 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- -1 two or more items Chemical class 0.000 description 1
- 229950004593 ublituximab Drugs 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Oncology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161504744P | 2011-07-06 | 2011-07-06 | |
| EP11172865.5 | 2011-07-06 | ||
| US61/504,744 | 2011-07-06 | ||
| EP11172865 | 2011-07-06 | ||
| PCT/EP2012/063207 WO2013004806A1 (en) | 2011-07-06 | 2012-07-06 | Therapeutic combinations of anti -cd20 and anti - gm - csf antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014520784A true JP2014520784A (ja) | 2014-08-25 |
| JP2014520784A5 JP2014520784A5 (enExample) | 2015-08-13 |
Family
ID=47436548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014517813A Pending JP2014520784A (ja) | 2011-07-06 | 2012-07-06 | 抗ｃｄ２０抗体と抗ｇｍ−ｃｓｆ抗体との治療的組合せおよびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20140234298A1 (enExample) |
| EP (1) | EP2729498A1 (enExample) |
| JP (1) | JP2014520784A (enExample) |
| KR (1) | KR20140061379A (enExample) |
| CN (1) | CN103827143A (enExample) |
| AU (2) | AU2012280267B2 (enExample) |
| BR (1) | BR112013033944A2 (enExample) |
| CA (1) | CA2839513A1 (enExample) |
| RU (1) | RU2013156435A (enExample) |
| WO (1) | WO2013004806A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018525339A (ja) * | 2015-06-24 | 2018-09-06 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | リンパ腫又は白血病におけるリンパ球増加症を誘導することにおける使用のためのヒトｃｓｆ−１ｒに対する抗体 |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109999195A (zh) | 2012-09-20 | 2019-07-12 | 莫弗系统股份公司 | 类风湿关节炎的治疗 |
| WO2016079276A1 (en) * | 2014-11-21 | 2016-05-26 | Takeda Gmbh | Use of an anti-gm-csf antagonist and an anti-ccr2 antagonist in the treatment of an infectious disease |
| EP3108897A1 (en) * | 2015-06-24 | 2016-12-28 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias |
| GB201519331D0 (en) * | 2015-11-02 | 2015-12-16 | Glaxosmithkline Ip Dev Ltd | Treatment paradigm |
| WO2018045117A1 (en) * | 2016-09-01 | 2018-03-08 | The Regents Of The University Of Colorado, A Body Corporate | Methods of treating eosinophilic gastrointestinal diseases |
| CN110087530A (zh) | 2016-12-07 | 2019-08-02 | 普罗根尼蒂公司 | 胃肠道检测方法、装置和系统 |
| EP4108183A1 (en) | 2017-03-30 | 2022-12-28 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| US10927168B2 (en) | 2017-10-02 | 2021-02-23 | Humanicen, Inc. | Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab |
| US11130805B2 (en) | 2017-10-02 | 2021-09-28 | Humanigen, Inc. | Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist |
| US10899831B2 (en) | 2017-10-02 | 2021-01-26 | Humanigen, Inc. | Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity |
| SG11202003096UA (en) | 2017-10-02 | 2020-05-28 | Humanigen Inc | Methods of treating immunotherapy-related toxicity using a gm-csf antagonist |
| US11655293B2 (en) * | 2018-02-22 | 2023-05-23 | Universitat Zurich | Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT |
| US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| WO2019246317A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease or condition in a tissue originating from the endoderm |
| WO2020078270A1 (en) | 2018-10-15 | 2020-04-23 | Elixiron Immunotherapeutics (hong Kong) Limited | Antibodies to granulocyte-macrophage colony stimulating factor and uses thereof |
| EP3873205A4 (en) * | 2018-10-31 | 2022-05-11 | Humanigen, Inc. | MATERIALS AND METHODS FOR TREATMENT OF CANCER |
| CA3117380A1 (en) * | 2018-11-09 | 2020-05-14 | Kiniksa Pharmaceuticals, Ltd. | Treatment for giant cell arteritis |
| CN116726362A (zh) | 2018-11-19 | 2023-09-12 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
| JP2022529536A (ja) * | 2019-04-25 | 2022-06-22 | アクティニウム ファーマシューティカルズ インコーポレイテッド | 悪性および非悪性血液疾患の治療のための免疫枯渇の組成物および方法 |
| CN115666704B (zh) | 2019-12-13 | 2025-09-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| EP4232162A1 (en) * | 2020-10-26 | 2023-08-30 | Kiniksa Pharmaceuticals, Ltd. | Treatment of cancers with gm-csf antagonists |
| JP7651145B2 (ja) * | 2021-04-20 | 2025-03-26 | コリア ユニバーシティ リサーチ アンド ビジネス ファウンデーション | 向上した癌細胞死滅効能を有する非対称抗体 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008545958A (ja) * | 2005-05-20 | 2008-12-18 | ジェネンテック・インコーポレーテッド | 自己免疫性疾患の被検体の生体試料の前処理 |
| JP2008545632A (ja) * | 2005-05-18 | 2008-12-18 | モルフォシス・アクチェンゲゼルシャフト | 抗ｇｍ−ｃｓｆ抗体とその使用 |
| JP2009526082A (ja) * | 2006-02-08 | 2009-07-16 | モルフォテック、インク． | 抗原性ｇｍ−ｃｓｆペプチドおよび抗ｇｍ−ｃｓｆ抗体 |
| WO2010093480A2 (en) * | 2009-02-16 | 2010-08-19 | Biolex Therapeutics, Inc. | Humanized anti-cd20 antibodies and methods of use |
| JP2010532749A (ja) * | 2007-06-07 | 2010-10-14 | サーモディクス ファーマシューティカルズ， インコーポレイテッド | 質量を削減した長時間作用剤形 |
| WO2010124163A2 (en) * | 2009-04-23 | 2010-10-28 | Theraclone Sciences, Inc. | Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| DE69329503T2 (de) * | 1992-11-13 | 2001-05-03 | Idec Pharma Corp | Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| CN1679934B (zh) | 1998-11-09 | 2012-09-05 | 生物基因Idec公司 | 使用抗cd20嵌合抗体治疗循环肿瘤细胞相关的血液恶性肿瘤 |
| ATE412433T1 (de) | 1999-02-12 | 2008-11-15 | Scripps Research Inst | Methoden zur behandlung von tumoren und metastasen unter verwendung einer anti-angiogenen und immun-therapien |
| US7321026B2 (en) | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
| ES2365606T3 (es) | 2002-02-13 | 2011-10-07 | Ludwig Institute For Cancer Research Ltd. | Anticuerpos contra gm-csf quiméricos. |
| CN100522999C (zh) | 2002-02-14 | 2009-08-05 | 免疫医疗公司 | 抗cd20抗体及其融合蛋白和使用方法 |
| PT1558648E (pt) | 2002-10-17 | 2012-04-23 | Genmab As | Anticorpos monoclonais humanos contra cd20 |
| EP2468774A3 (en) | 2005-04-18 | 2013-01-02 | Amgen Research (Munich) GmbH | Antibody neutralizers of human granulocyte macrophage colony stimulating factor |
| JP4736037B2 (ja) | 2005-10-26 | 2011-07-27 | 株式会社イーベック | ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分 |
| US20070136826A1 (en) | 2005-12-02 | 2007-06-14 | Biogen Idec Inc. | Anti-mouse CD20 antibodies and uses thereof |
| CN101605547A (zh) * | 2006-11-21 | 2009-12-16 | 卡罗拜奥斯制药公司 | 使用gm-csf拮抗剂治疗慢性炎症疾病的方法 |
| CA2687791A1 (en) | 2007-05-23 | 2008-11-27 | Crc For Asthma And Airways Ltd | Neutralizing antibodies |
| TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| WO2009062238A1 (en) | 2007-11-12 | 2009-05-22 | Crc For Asthma And Airways Ltd | Epitope for neutralizing antibodies |
| ME01005B (me) | 2007-11-13 | 2012-10-20 | Boehringer Ingelheim Int | MONOKLONSKA ANTITIJELA KOJA SE VEZUJU ZA HGM-CSF l MEDICINSKI PREPARATI KOJI IH SADRŽE |
| DK2280732T3 (en) | 2008-04-28 | 2019-01-28 | Humanigen Inc | ANTIBODIES AGAINST GRANULOCYT MACROPHAG COLONY STIMULATING FACTOR |
| ES2557494T3 (es) | 2008-04-29 | 2016-01-26 | Amgen Research (Munich) Gmbh | Inhibidores de GM-CSF e IL-17 para terapia |
| US20100122819A1 (en) | 2008-11-17 | 2010-05-20 | Baker Hughes Incorporated | Inserts with Swellable Elastomer Seals for Side Pocket Mandrels |
| AR075982A1 (es) | 2009-03-31 | 2011-05-11 | Roche Glycart Ag | Terapia de combinacion de un anticuerpo afucosilado y una o mas de las citoquinas seleccionadas de gm- csf humano, m -csf humano y/o il-3 humano y composicion |
-
2012
- 2012-07-06 BR BR112013033944A patent/BR112013033944A2/pt not_active IP Right Cessation
- 2012-07-06 KR KR1020147003186A patent/KR20140061379A/ko not_active Withdrawn
- 2012-07-06 AU AU2012280267A patent/AU2012280267B2/en not_active Ceased
- 2012-07-06 JP JP2014517813A patent/JP2014520784A/ja active Pending
- 2012-07-06 CN CN201280033421.3A patent/CN103827143A/zh active Pending
- 2012-07-06 US US14/130,667 patent/US20140234298A1/en not_active Abandoned
- 2012-07-06 EP EP12735498.3A patent/EP2729498A1/en not_active Withdrawn
- 2012-07-06 CA CA2839513A patent/CA2839513A1/en not_active Abandoned
- 2012-07-06 RU RU2013156435/10A patent/RU2013156435A/ru not_active Application Discontinuation
- 2012-07-06 WO PCT/EP2012/063207 patent/WO2013004806A1/en not_active Ceased
-
2016
- 2016-03-18 AU AU2016201736A patent/AU2016201736A1/en not_active Abandoned
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008545632A (ja) * | 2005-05-18 | 2008-12-18 | モルフォシス・アクチェンゲゼルシャフト | 抗ｇｍ−ｃｓｆ抗体とその使用 |
| JP2008545958A (ja) * | 2005-05-20 | 2008-12-18 | ジェネンテック・インコーポレーテッド | 自己免疫性疾患の被検体の生体試料の前処理 |
| JP2009526082A (ja) * | 2006-02-08 | 2009-07-16 | モルフォテック、インク． | 抗原性ｇｍ−ｃｓｆペプチドおよび抗ｇｍ−ｃｓｆ抗体 |
| JP2010532749A (ja) * | 2007-06-07 | 2010-10-14 | サーモディクス ファーマシューティカルズ， インコーポレイテッド | 質量を削減した長時間作用剤形 |
| WO2010093480A2 (en) * | 2009-02-16 | 2010-08-19 | Biolex Therapeutics, Inc. | Humanized anti-cd20 antibodies and methods of use |
| WO2010124163A2 (en) * | 2009-04-23 | 2010-10-28 | Theraclone Sciences, Inc. | Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies |
Non-Patent Citations (2)
| Title |
|---|
| AM. J. RESPIR. CRIT. CARE MED., vol. 182, no. 1, JPN6016015786, 2010, pages 49 - 61, ISSN: 0003307913 * |
| J. IMMUNOL., vol. 164, no. 7, JPN6016015785, 2000, pages 3887 - 3893, ISSN: 0003307912 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018525339A (ja) * | 2015-06-24 | 2018-09-06 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | リンパ腫又は白血病におけるリンパ球増加症を誘導することにおける使用のためのヒトｃｓｆ−１ｒに対する抗体 |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112013033944A2 (pt) | 2017-12-19 |
| WO2013004806A1 (en) | 2013-01-10 |
| EP2729498A1 (en) | 2014-05-14 |
| CA2839513A1 (en) | 2013-01-10 |
| AU2012280267B2 (en) | 2016-04-21 |
| AU2016201736A1 (en) | 2016-04-07 |
| CN103827143A (zh) | 2014-05-28 |
| US20140234298A1 (en) | 2014-08-21 |
| AU2012280267A1 (en) | 2014-01-16 |
| KR20140061379A (ko) | 2014-05-21 |
| RU2013156435A (ru) | 2015-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012280267B2 (en) | Therapeutic combinations of anti-cd20 and anti-gm-csf antibodies and uses thereof | |
| JP6486887B2 (ja) | 皮下投与される抗ｉｌ−６受容体抗体 | |
| EP3747464B1 (en) | Methods for treating progressive multiple sclerosis using an anti-cd20 antibody | |
| US20240366756A1 (en) | Combinations and uses thereof | |
| US20230227570A1 (en) | Bispecific antibodies against cd3 and cd20 | |
| JP7288927B2 (ja) | 乾癬性関節炎患者における構造的損傷の進行を阻害するためのｉｌ－１７アンタゴニストの使用 | |
| JP2024001125A (ja) | Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法 | |
| JP2017519757A (ja) | 慢性リンパ球性白血病（ｃｌｌ）の処置 | |
| KR20230045613A (ko) | Covid-19의 치료 및 예방을 위한 sars-cov-2 항체 | |
| US20190322734A1 (en) | Treatment paradigm | |
| CN108431038A (zh) | 治疗多发性硬化的方法 | |
| JP2024525870A (ja) | 抗ｐｌａ２ｒ自己抗体媒介膜性腎症の治療 | |
| JPWO2023031403A5 (enExample) | ||
| US20240270862A1 (en) | Use of b cell depleting agents for the treatment of rheumatic heart disease | |
| US20250134997A1 (en) | Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy in ctdna high risk patients | |
| WO2025215124A2 (en) | Combination treatment of glofitamab and chemotherapy | |
| HK40110169A (en) | Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients | |
| WO2025222102A1 (en) | Therapeutic combinations of acalabrutinib and a multispecific antibody to treat b-cell malignancies | |
| CN118076640A (zh) | 抗-pla2r自身抗体介导的膜性肾病的治疗 | |
| JP2020055830A (ja) | 慢性リンパ球性白血病（ｃｌｌ）の処置 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20140623 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20140623 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150626 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150626 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160510 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20170110 |